Management of venous thromboembolic disease in the lower limb.
Thromboembolic disease continues to cause significant morbidity and mortality in our community, despite extensive research into the aetiological factors and significant resources invested in the development of pharmacological agents for treating this condition. Development of more sensitive and specific modalities for identifying venous thromboses has improved their early detection, particularly in the commonest site, the lower limb. A rational evidence-based management pathway has not been formulated as debate continues over the most appropriate method of treatment. This review outlines the pathophysiology of the disease, provides a clinical pathway for the management of lower limb thromboembolic disease using reliable available evidence and briefly discusses the efficacy of drug therapy.
May
C R
CR
Department of Emergency Medicine, Royal Brisbane Hospital, Queensland, Australia. ChrisR_May@health.qld.gov.au
D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D007866:Leg / Q000098:blood supply*; D011655:Pulmonary Embolism / Q000209:etiology; D012307:Risk Factors; D013923:Thromboembolism / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology
D005343:Fibrinolytic Agents; D006493:Heparin